Biotech companies are finding generative AI has applications in drug discovery, protein engineering, and personalized medicine.
A recent research report has outlined just how popular generative AI has become with biotech companies. Its use in the market is expected to reach a value of around $472 million by 2032, with a compound annual growth rate (CAGR) of 24.9% during the forecast period. Interest in the technology is broad with many application areas being explored.
Why biotech is embracing generative AI
Generative AI is gaining significant attention thanks to its ability to simulate and generate novel molecules, proteins, and genetic sequences. This ability has applications in drug discovery, protein engineering, and personalized medicine. These algorithms create virtual libraries of comments that researchers can quickly screen to accelerate the drug discovery pipeline. They can also explore vast sequences and structures which could revolutionize fields like enzyme catalysis and antibody engineering.
An exciting possibility lies in the field of personalized medicine. Generative AI can analyze patient data and genetic information to produce tailored treatment plans and optimize therapies. They also help keep patients safer by minimizing adverse reactions by predicting drug responses for individual patients.
